WindRose completes recapitalization of Verified Clinical Trials
WindRose Health Investors has recapitalized Verified Clinical Trials, a provider of clinical trial subject registry solutions, with founders staying involved.
WindRose Health Investors has completed the recapitalization of Verified Clinical Trials, which provides solutions addressing patient safety, compliance and data integrity from patient enrollment through study completion. Under the transaction, WindRose will appoint Howard Miller as chief executive officer.
Co-founders Mitchell Efros and Kerri Weingard will remain actively involved in the business to support its long-term growth strategy. WindRose said the investment positions the company to capitalize on growing adoption of its solutions and to develop additional data and analytics capabilities for pharmaceutical sponsors, CROs and clinical trial sites.
Cantor Fitzgerald & Co. acted as exclusive financial advisor to Verified Clinical Trials, with McDermott Will & Schulte LLP as legal advisor. Latham & Watkins LLP advised WindRose. The terms were not disclosed.
Deal facts
- Target
- Verified Clinical Trials
- Business
- Provider of clinical trial subject registry solutions that detect and prevent duplicate enrollment and protocol violations
- Investor
- WindRose Health Investors
- Sponsor
- WindRose Health Investors
- Deal type
- Recap
- Advisers
- Cantor Fitzgerald & Co. financial adviser to Verified Clinical Trials
- McDermott Will & Schulte LLP legal counsel to Verified Clinical Trials
- Latham & Watkins LLP legal counsel to WindRose Health Investors
- Status
- Completed
- Announced
- Thursday, August 6, 2026
Sources
- PR NewswireAug 6, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.